Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Xiehe Group To Set Up Base In Shenzhen

This article was originally published in PharmAsia News

Executive Summary

China's leading biopharmaceutical company, Shenyang Xiehe Group, has announced it will set up a wholly-owned subsidiary in Shenzhen High-Tech Industrial Park; it will also site its future R&D and international base in the city. Xiehe Group, a multinational conglomerate with 33 subsidiaries worldwide, integrates R&D, production and trading for health care items, biopharmaceuticals and other high-tech products. Its product value is expected to reach RMB 4 billion by 2010. The latest move is an important step in Xiehe Group's rapid growth as it will tap on Shenzhen's advantages in location and manufacturing to reap its R&D translational output as well as expand sales. The company has already established R&D centers in the U.S., Hong Kong and Shenyang. (Click here for more - Chinese Language)

You may also be interested in...



US FDA Oncology AdComm's Pediatric Study Reviews Go Virtual

ODAC's 17-18 June discussion of pediatric development plans for four investigational oncology agents will serve as a trial run of the technology platform and logistics for any future application-specific virtual advisory committee meeting, but without the stress associated with a pending application and a user fee deadline.

Merck Is Counting On Keytruda To Establish Its Anti-TIGIT Drug

Vibostolimab is less advanced than Roche’s competing tiragolumab, but Merck thinks the combo of its anti-TIGIT and Keytruda will offer a better therapeutic profile.

EU Unveils Ambitions To ‘Future-Proof’ Entire Drug Regulatory Framework

Ambitious efforts to make the EU more resilient to future challenges, such as health threats, drug supply problems, scientific advances and growing medicine costs, have taken a step forward with the publication of a roadmap for a wide-ranging Pharmaceutical Strategy to be adopted by the European Commission later in the year.

UsernamePublicRestriction

Register

LL1132553

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel